Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 33Recurrence 8Lymphoma, Large B-Cell, Diffuse 4Immunoglobulin Light-chain Amyloidosis 4Neoplasms, Plasma Cell 2Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2Sarcoma, Kaposi 1Proteostasis Deficiencies 1Plasmablastic Lymphoma 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Epstein-Barr Virus Infections 1Burkitt Lymphoma 1Amyloidosis 1Acquired Immunodeficiency Syndrome 1

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Proteostasis Deficiencies × pomalidomide × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡